KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. - Wikidata - wikimedia - TriplyDB

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

http://www.wikidata.org/entity/Q27824868

about

Genetic alteration and mutation profiling of circulating cell-free tumor DNA (cfDNA) for diagnosis and targeted therapy of gastrointestinal stromal tumors Targeted therapy of gastrointestinal stromal tumours Clinicopathological significance of c-KIT mutation in gastrointestinal stromal tumors: a systematic review and meta-analysis Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges CIViC database Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations Current management and prognostic features for gastrointestinal stromal tumor (GIST)ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.A nomogram to predict disease-free survival after surgical resection of GIST The C-kit receptor-mediated signal transduction and tumor-related diseases Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial.A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report.Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations.Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data.Early outcomes of exon 11 mutants in GIST treated with standard dose Imatinib.Gastrointestinal stromal tumor and its targeted therapeutics.UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST).Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors.Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib.Clinical and molecular characteristics of gastrointestinal stromal tumors in the pediatric and young adult population Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.Molecular pathology of sarcomas: concepts and clinical implications Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.Imatinib: a breakthrough of targeted therapy in cancer.Evaluation of self-reported progression and correlation of imatinib dose to survival in patients with metastatic gastrointestinal stromal tumors: an open cohort study Mucosal melanomas in the elderly: challenging cases and review of the literature.Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review.Molecular basis and management of gastrointestinal stromal tumors NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type

P2860

2f9b3cb933956fb1a68b24672cd3f8aab0530d2d

P248

Q26738567-B33B471E-1953-410D-9098-03ECD615E5BB Q26745633-5C639DA9-8DA3-4EE2-B72C-C11315461E61 Q26782641-CDE3E1BF-3DB8-4848-8AC2-08B3599E0934 Q26799387-D5B6CC8A-2493-4C38-B4C9-CE58D35C2D3B Q26823978-C0196221-A903-46E4-AC5C-FBBBB30C8585 Q27612411-2E2D55B9-79DC-49F1-8C4C-B6CF73510C3A Q27851455-92DD9B15-C90F-4BB4-90EE-E47FDF256CFB Q27851995-07F68DDD-99EB-47A8-8CF4-59034D4A8810 Q27853181-1034BF01-45CA-48FA-A90A-EC41C812B217 Q28247449-1BF15C14-FBE5-4E3F-B214-F0F20C3C3FD9 Q28391684-AD667B4D-DA5E-4CF3-8DE1-8C1B1379E1A3 Q28485315-5EA39501-FBCC-4D07-8E8D-62637C3CDAA0 Q30245586-22F4F293-50B9-4146-8C2B-DA15A5D9F989 Q30366151-5B3D9471-A9A8-42E9-AE3F-97ABE5FBB31E Q30419298-7C3A698D-D9EF-4325-ACB9-33FA8FE8883F Q30485073-0BA17971-D8CD-4CB0-A319-C47D2EE3EA33 Q33168544-0D1D8F81-451F-4E84-8603-85823432F4D4 Q33269497-491C356F-D8B0-42BD-B360-81AF0FD34ADD Q33403257-CE15738A-BE1D-4D4E-89F7-61C02F0192CC Q33515723-9116F0E0-B5DA-4493-BB60-29FBAED1160B Q33575310-F614A1E7-1D47-4437-BE4F-2A651553D974 Q33579642-79BB69CF-39B0-4730-89AB-D00D524D8FAA Q33612778-19D917D1-4500-41D5-B604-5BA0C7086C89 Q33624278-689E527F-4784-49BD-B98B-90F42C52B88A Q33633409-4C085055-AC57-4EE2-B57F-AF91D6E17E98 Q33644791-0F0D0213-BAB0-4635-88A1-477BEBDB280F Q33654872-3DFE0CB4-C173-411E-A9E8-45F422383D92 Q33654894-61DC497E-4CB9-4241-877E-61ADCAD2DF24 Q33688157-452791A4-696F-4C59-BB90-FC26E470B616 Q33699901-DCF77935-F7B4-4643-BC76-09C70EF2F6D5 Q33710999-11FFB140-66D5-459F-A141-387F082C46D8 Q33747261-B1FDC025-A753-4613-AD8A-DA148578B447 Q33756542-A63FEED1-02AA-4738-9BEE-A17FC5E6892B Q33769490-04F57EE8-D6EE-4244-BAB0-F380803D1659 Q33777447-CBBE320F-C5B7-406C-8087-825791303F92 Q33849805-AF202450-39B2-4044-9411-D2721D1076E0 Q33895608-567980BF-76FB-490E-A60F-2FD036824220 Q33903598-817B6A5A-F1F6-42DA-98F9-79BFF1C5CB7B Q33921067-C44BE56D-884F-448C-AA99-9AE22E8CCAC4 Q33995919-E24C0AAB-2100-4EE8-AD58-F5CC819B7104

P2860

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

http://www.wikidata.org/entity/Q27824868

description

2006 nî lūn-bûn

@nan

2006 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

KIT mutations and dose selecti ...... trointestinal stromal tumours.

@ast

KIT mutations and dose selecti ...... trointestinal stromal tumours.

@en

KIT mutations and dose selecti ...... trointestinal stromal tumours.

@nl

type

label

KIT mutations and dose selecti ...... trointestinal stromal tumours.

@ast

KIT mutations and dose selecti ...... trointestinal stromal tumours.

@en

KIT mutations and dose selecti ...... trointestinal stromal tumours.

@nl

prefLabel

KIT mutations and dose selecti ...... trointestinal stromal tumours.

@ast

KIT mutations and dose selecti ...... trointestinal stromal tumours.

@en

KIT mutations and dose selecti ...... trointestinal stromal tumours.

@nl

P1433

Q27824868-8FDFD630-4703-4565-9585-9709A9D49B7E

P1476

Q27824868-ABA6AE5B-0B8D-4B9C-82F4-31C14E56AF78

P2093

Q27824868-01E73F2C-30D5-4899-8A5F-D7CC38EBE962

Q27824868-3CEF51C7-AF32-4E02-8CDD-4983BD7CC567

Q27824868-48935E49-1B67-443D-8EE0-D5B4D2FEA147

Q27824868-58D79A52-969A-4EA9-A63E-E8CA70AD0F60

Q27824868-59B49A3B-7BA3-46D0-BD63-1BB1720E6A9A

Q27824868-5E9522E5-D56C-4339-ABC2-CFE2156186A2

Q27824868-7351BF7F-5963-4E83-B7DE-55330C508A9B

Q27824868-9A5833C2-69A8-4762-AF0D-DE0D300BDE77

Q27824868-B312EB4D-A9B9-42D7-A5AB-45368BCD4D88

Q27824868-ED776BCC-CFF0-4AC4-BDF9-E58715680A5C

P304

Q27824868-2D812F1A-EB5C-4696-A0EA-AC52C5C46DFC

P31

Q27824868-4DE48AA8-2CDF-46C6-A193-6EE66FB6820D

P3181

Q27824868-77067505-1C1D-43D8-BDE3-3730793CB6CE

P356

Q27824868-17C3588D-9047-46A8-8927-DFA07A25B964

P433

Q27824868-5E13C27A-4338-4C1D-ABF3-A4773600EE10

P478

Q27824868-1A385E88-D9F2-4936-83F3-4267FE39280C

P50

Q27824868-228DBA20-1E02-4795-B625-6C5A95DBE7B1

Q27824868-32B6B3CC-8AFD-4FE3-81F3-67B033B3C3BF

Q27824868-6715D63D-D4C2-44B9-ACC6-10B26C315127

Q27824868-B8F0CE5F-EF2A-49C8-BE4F-CEE497EA45DA

Q27824868-F3202B44-6A0A-40AC-B7B4-0412999C2E04

P577

Q27824868-7C5425B5-F400-45AF-9C1B-04C051EE0E50

P5875

Q27824868-4A63AE1A-3E14-4D2B-A7B6-9B2FF987B4F7

P698

Q27824868-1D43E90A-AB5A-4EF7-8288-B0EFA0972880

P921

Q27824868-2837AF92-BB02-4170-8554-64C710FEC460

P3181

P356

J.EJCA.2006.01.030

P1433

European Journal of Cancer

P1476

KIT mutations and dose selecti ...... trointestinal stromal tumours.

@en

P2093

Allan T van Oosterom

http://www.w3.org/2001/XMLSchema#string

Anne Hagemeijer

http://www.w3.org/2001/XMLSchema#string

Ian Judson

http://www.w3.org/2001/XMLSchema#string

Jaap Verweij

http://www.w3.org/2001/XMLSchema#string

John Zalcberg

http://www.w3.org/2001/XMLSchema#string

Marcus Schlemmer

http://www.w3.org/2001/XMLSchema#string

Martine Van Glabbeke

http://www.w3.org/2001/XMLSchema#string

Michel Stul

http://www.w3.org/2001/XMLSchema#string

Peter Hohenberger

http://www.w3.org/2001/XMLSchema#string

Serge Leyvraz

http://www.w3.org/2001/XMLSchema#string

P304

1093-103

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

389377

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.EJCA.2006.01.030

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Giovanni Casali

Maria Debiec-Rychter

P577

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7155045

http://www.w3.org/2001/XMLSchema#string

P698

16624552

http://www.w3.org/2001/XMLSchema#string

P921